These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38347617)

  • 1. Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility.
    Weng CW; Li JH; Tsai JY; Lin SH; Chang GC; Liu CC; Chen JJ
    Am J Cancer Res; 2020; 10(6):1668-1690. PubMed ID: 32642283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Drug Discovery for Isoxazole Based VEGFR2 Inhibition.
    Patil SM; Mahadik I; Bhandari SV; Asgaonkar KD; Randive VD; Edake AM
    Curr Drug Discov Technol; 2024 May; ():. PubMed ID: 38798213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico Exploration of a Novel ICMT Inhibitor with More Solubility than Cysmethynil against Membrane Localization of KRAS Mutant in Colorectal Cancer.
    Mouhcine M; Kadil Y; Segmani I; Rahmoune I; Filali H
    Curr Comput Aided Drug Des; 2024 Jun; ():. PubMed ID: 38835128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hit discovery of potential CDK8 inhibitors and analysis of amino acid mutations for cancer therapy through computer-aided drug discovery.
    Aghahasani R; Shiri F; Kamaladiny H; Haddadi F; Pirhadi S
    BMC Chem; 2024 Apr; 18(1):73. PubMed ID: 38615023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies.
    Rampogu S; Baek A; Son M; Park C; Yoon S; Parate S; Lee KW
    ACS Omega; 2020 Feb; 5(4):1773-1781. PubMed ID: 32039312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico pharmacokinetic and molecular docking studies of small molecules derived from Indigofera aspalathoides Vahl targeting receptor tyrosine kinases.
    Paramashivam SK; Elayaperumal K; Natarajan BB; Ramamoorthy MD; Balasubramanian S; Dhiraviam KN
    Bioinformation; 2015; 11(2):73-84. PubMed ID: 25848167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-aware dual-target drug design through collaborative learning of pharmacophore combination and molecular simulation.
    Chen S; Xie J; Ye R; Xu DD; Yang Y
    Chem Sci; 2024 Jul; 15(27):10366-10380. PubMed ID: 38994407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-target virtual screening by pharmacophore elucidation and molecular shape filtering.
    Moser D; Wisniewska JM; Hahn S; Achenbach J; Buscató El; Klingler FM; Hofmann B; Steinhilber D; Proschak E
    ACS Med Chem Lett; 2012 Feb; 3(2):155-8. PubMed ID: 24900445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction: Construction of antifungal dual-target (SE, CYP51) pharmacophore models and the discovery of novel antifungal inhibitors.
    Dong Y; Liu M; Wang J; Ding Z; Sun B
    RSC Adv; 2024 Jul; 14(32):23559. PubMed ID: 39071476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-Based Pharmacophore Modeling, Molecular Docking, and Molecular Dynamic Studies of Dual Tyrosine Kinase Inhibitor of EGFR and VEGFR2.
    Sangande F; Julianti E; Tjahjono DH
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational insights into allosteric inhibition of focal adhesion kinase: A combined pharmacophore modeling and molecular dynamics approach.
    Kumar V; Singh P; Parate S; Singh R; Ro HS; Song KS; Lee KW; Park YM
    J Mol Graph Model; 2024 Jul; 130():108789. PubMed ID: 38718434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potentially high drug-like VEGFR2/c-Met dual-target type II kinase inhibitors with symmetric skeletons based on structural screening.
    Xie J; Zhang X; Meng D; Li Y; Deng P
    J Biomol Struct Dyn; 2024; 42(3):1249-1267. PubMed ID: 37042992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of dual kinase inhibitors targeting VEGFR2 and FAK: structure-based pharmacophore modeling, virtual screening, and molecular docking studies.
    Fouad MA; Osman AA; Abdelhamid NM; Rashad MW; Nabawy AY; El Kerdawy AM
    BMC Chem; 2024 Feb; 18(1):29. PubMed ID: 38347617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
    El Kerdawy AM; Osman AA; Zaater MA
    J Mol Model; 2019 May; 25(6):171. PubMed ID: 31129879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.